CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Domperidone

多潘立酮 杂质对照品Domperidone Impurities

EP26 个杂质条目26 impurity entries

本页汇总 多潘立酮 的 26 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 26 impurity reference standards of Domperidone with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 多潘立酮(Domperidone)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesMATLAB-candexch algorithm-enhanced UV spectrophotometric-chemometric models for green, blue, and white determination of cinnarizine, domperidone, and carcinogenic impurity in pharmaceuticals: NQS assessment and UN-SDGs integration
    BMC chemistry · 2026 · Ghanem HN et al.  ·  PMID 41968313  ·  DOI
  2. 杂质研究Impurity studiesThe ultra-performance liquid chromatography determination of domperidone and its process-related impurities
    Journal of chromatographic science · 2015 · Curtin Whelan L et al.  ·  PMID 24904093  ·  DOI
  3. 杂质研究Impurity studiesSeparation of Unprecedented Degradants of Domperidone by Ultra-Performance Convergence Chromatography and Their Structure Elucidation
    Journal of chromatographic science · 2019 · Mutha VVSRNAK et al.  ·  PMID 31504287  ·  DOI
  4. 分析方法Analytical MethodsSimultaneous determination of domperidone and Itopride in pharmaceuticals and human plasma using RP-HPLC/UV detection: Method development, validation and application of the method in in-vivo evaluation of fast dispersible tablets
    Journal of pharmaceutical and biomedical analysis · 2016 · Khan A et al.  ·  PMID 26773534  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisOptimisation of a Greener-Approach for the Synthesis of Cyclodextrin-Based Nanosponges for the Solubility Enhancement of Domperidone, a BCS Class II Drug
    Pharmaceuticals (Basel, Switzerland) · 2023 · Vij M et al.  ·  PMID 37111324  ·  DOI

多潘立酮 —— 原料药与杂质对照品Domperidone — drug substance & impurities

共 27 个条目(含原料药本体)27 items incl. the drug substance
Domperidone structure
EP原料药 APIAPI
多潘立酮Domperidone
Domperidone
CAS No.57808-66-9
Chemical FormulaC22H24ClN5O2
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 1 (Domperidone EP Impurity A) structure
EPA
多潘立酮杂质1 (多潘立酮EP杂质A)Domperidone Impurity 1 (Domperidone EP Impurity A)
Domperidone Impurity 1 (Domperidone EP Impurity A)
CAS No.53786-28-0
Chemical FormulaC12H14ClN3O
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 2 (Domperidone EP Impurity B) structure
EPB
多潘立酮杂质2 (多潘立酮EP杂质B)Domperidone Impurity 2 (Domperidone EP Impurity B)
Domperidone Impurity 2 (Domperidone EP Impurity B)
CAS No.1346598-11-5
Chemical FormulaC13H14ClN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 4 (Domperidone EP Impurity D) structure
EPD
多潘立酮杂质4 (多潘立酮EP杂质D)Domperidone Impurity 4 (Domperidone EP Impurity D)
Domperidone Impurity 4 (Domperidone EP Impurity D)
CAS No.1614255-34-3
Chemical FormulaC32H34ClN7O3
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 5 (Domperidone EP Impurity E) structure
EPE
多潘立酮杂质5 (多潘立酮EP杂质E)Domperidone Impurity 5 (Domperidone EP Impurity E)
Domperidone Impurity 5 (Domperidone EP Impurity E)
CAS No.1346602-50-3
Chemical FormulaC32H34ClN7O3
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 6 (Domperidone EP Impurity F) structure
EPF
多潘立酮杂质6 (多潘立酮EP杂质F)Domperidone Impurity 6 (Domperidone EP Impurity F)
Domperidone Impurity 6 (Domperidone EP Impurity F)
CAS No.1391053-55-6
Chemical FormulaC37H42Cl2N8O3
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 7 structure
7
多潘立酮杂质7Domperidone Impurity 7
Domperidone Impurity 7
CAS No.53786-45-1
Chemical FormulaC14H20ClN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 8 structure
8
多潘立酮杂质8Domperidone Impurity 8
Domperidone Impurity 8
CAS No.53786-44-0
Chemical FormulaC14H18ClN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 9 structure
9
多潘立酮杂质9Domperidone Impurity 9
Domperidone Impurity 9
CAS No.62780-89-6
Chemical FormulaC10H11ClN2O
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 10 structure
10
多潘立酮杂质10Domperidone Impurity 10
Domperidone Impurity 10
CAS No.72798-66-4
Chemical FormulaC10H10N2O
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 11 structure
11
多潘立酮杂质11Domperidone Impurity 11
Domperidone Impurity 11
CAS No.62780-84-1
Chemical FormulaC13H15ClN2O
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 12 structure
12
多潘立酮杂质12Domperidone Impurity 12
Domperidone Impurity 12
CAS No.53786-46-2
Chemical FormulaC15H18ClN3O3
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 13 structure
13
多潘立酮杂质13Domperidone Impurity 13
Domperidone Impurity 13
CAS No.39677-10-6
Chemical FormulaC17H16N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 14 structure
14
多潘立酮杂质14Domperidone Impurity 14
Domperidone Impurity 14
CAS No.62780-92-1
Chemical FormulaC10H12N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 15 structure
15
多潘立酮杂质15Domperidone Impurity 15
Domperidone Impurity 15
CAS No.142799-22-2
Chemical FormulaC13H16Cl2N2O
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 16 structure
16
多潘立酮杂质16Domperidone Impurity 16
Domperidone Impurity 16
CAS No.103784-04-9
Chemical FormulaC10H11BrN2O
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 17 structure
17
多潘立酮杂质17Domperidone Impurity 17
Domperidone Impurity 17
CAS No.615-15-6
Chemical FormulaC8H8N2
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 18 structure
18
多潘立酮杂质18Domperidone Impurity 18
Domperidone Impurity 18
CAS No.85443-52-3
Chemical FormulaC14H19N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 19 structure
19
多潘立酮杂质19Domperidone Impurity 19
Domperidone Impurity 19
CAS No.107618-26-8
Chemical FormulaC14H20ClN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 20 structure
20
多潘立酮杂质20Domperidone Impurity 20
Domperidone Impurity 20
CAS No.87120-77-2
Chemical FormulaC14H21N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 21 structure
21
多潘立酮杂质21Domperidone Impurity 21
Domperidone Impurity 21
CAS No.118435-03-3
Chemical FormulaC22H24ClN5O3
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 25 structure
25
多潘立酮杂质25Domperidone Impurity 25
Domperidone Impurity 25
CAS No.1392208-05-7
Chemical FormulaC12H14ClN3O
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 27 structure
27
多潘立酮杂质27Domperidone Impurity 27
Domperidone Impurity 27
CAS No.34840-27-2
Chemical FormulaC9H12N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 36 structure
36
多潘立酮杂质36Domperidone Impurity 36
Domperidone Impurity 36
CAS No.736085-12-4
Chemical FormulaC11H14ClN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 40 structure
40
多潘立酮杂质40Domperidone Impurity 40
Domperidone Impurity 40
CAS No.22219-23-4
Chemical FormulaC9H10N2O
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 46 structure
46
多潘立酮杂质46Domperidone Impurity 46
Domperidone Impurity 46
CAS No.58859-52-2
Chemical FormulaC12H14ClN3O
Purity>95%询价On request
10mg25mg50mg100mg
Domperidone Impurity 47 structure
47
多潘立酮杂质47Domperidone Impurity 47
Domperidone Impurity 47
CAS No.58859-55-5
Chemical FormulaC12H14ClN3O
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

多潘立酮 —— 研究文献与合成路线Domperidone — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 多潘立酮 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Domperidone. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. A Single Gradient Stability-Indicating Reversed-Phase LC Method for the Estimation of Impurities in Omeprazole and Domperidone Capsules
    Seshadri RK, Raghavaraju TV, Chakravarthy IE · Scientia pharmaceutica · 2013 · 被引 7cited 7
  2. Stability indicating simultaneous determination of domperidone (DP), methylparaben (MP) and propylparaben by high performance liquid chromatography (HPLC)
    Ali MS, Ghori M, Khatri AR · Journal of pharmaceutical and biomedical analysis · 2006 · 被引 9cited 9
  3. MATLAB-candexch algorithm-enhanced UV spectrophotometric-chemometric models for green, blue, and white determination of cinnarizine, domperidone, and carcinogenic impurity in pharmaceuticals: NQS assessment and UN-SDGs integration
    Ghanem HN, El-Zaher AA, Taha EA, et al. · BMC chemistry · 2026
  4. Separation of Unprecedented Degradants of Domperidone by Ultra-Performance Convergence Chromatography and Their Structure Elucidation
    Mutha VVSRNAK, Chandra C, Vijayabhaskar B, et al. · Journal of chromatographic science · 2019
  5. The ultra-performance liquid chromatography determination of domperidone and its process-related impurities
    Curtin Whelan L, Geary M, Wharton M, et al. · Journal of chromatographic science · 2015 · 被引 1cited 1
  6. Second-derivative synchronous fluorometric method for the simultaneous determination of cinnarizine and domperidone in pharmaceutical preparations. Application to biological fluids
    Walash MI, Belal F, El-Enany N, et al. · Journal of fluorescence · 2008 · 被引 27cited 27

合成与制备工艺专利Synthesis & process patents

  1. Synthesis of domperidone maleate
    LI ZHAN LIU · 公开号 CN1810805CN1810805 · 2006
  2. Domperidone sustained-release dropping pill and preparation method thereof
    YUNZHI QU · 公开号 CN101269030CN101269030 · 2008
  3. Slow released omeprazole/domperidone preparation and its preparing process and application
    ZHOU XIA · 公开号 CN1857265CN1857265 · 2006
  4. Dropping pills containing domperidone and method for preparing the same
    YONGQIANG LI, YONGFENG ZHENG · 公开号 CN101194905CN101194905 · 2008
  5. Domperidone drip pills and its preparation method
    QU YUNZHI XU · 公开号 CN1823774CN1823774 · 2006

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

多潘立酮 杂质谱研究要点Domperidone — impurity profiling notes

下面这些是拿到 多潘立酮 的 27 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 27 impurity entries for Domperidone, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances